A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients with Late Stage Acute Myeloid Leukaemia.

Trial Profile

A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients with Late Stage Acute Myeloid Leukaemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Elacytarabine (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms CLAVELA
  • Sponsors Aqualis
  • Most Recent Events

    • 19 May 2014 Final results published in the Journal of Clinical Oncology.
    • 01 Apr 2013 Primary endpoint 'Superiority of elacytarabine to investigator's choice of treatment in overall survival rate' has not been met, according to a Clavis pharma media release.
    • 01 Apr 2013 Top-line results reported in a Clavis Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top